| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2017 | Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
| CANCER RESEARCH AND TREATMENT |
| 2022 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
| CLINICAL LUNG CANCER |
| 2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
| 2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| YONSEI MEDICAL JOURNAL |
| 2023 | Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
| FRONTIERS IN ONCOLOGY |
| 2020 | Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
| CANCER RESEARCH AND TREATMENT |
| 2022 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Real-world Use of Osimertinib in Non-Small Cell Lung Cancer: ASTRIS Study Korean Subgroup Analysis | CURRENT MEDICAL RESEARCH AND OPINION |
| 2015 | Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells | LUNG CANCER |
| 2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
| 2024 | Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2013 | Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma | FUTURE ONCOLOGY |
| 2021 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2014 | Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2014 | Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
| PLOS ONE |
| 2021 | Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? | JOURNAL OF THORACIC ONCOLOGY |
| 2017 | Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer | LUNG CANCER |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
| 2004 | Subacute Bacterial Endocarditis Associated with Upper Endoscopy
| YONSEI MEDICAL JOURNAL |
| 2016 | Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
| ONCOTARGET |
| 2017 | Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
| JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
| 2023 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
| 2020 | Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEW ENGLAND JOURNAL OF MEDICINE |
| 2016 | The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma
| CANCER RESEARCH AND TREATMENT |
| 2008 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2012 | The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
| 2015 | The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer | LUNG CANCER |
| 2013 | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2013 | The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
| YONSEI MEDICAL JOURNAL |
| 2013 | The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients | JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY |
| 2008 | The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. | LUNG CANCER |
| 2012 | The prognostic factors of resected non-small cell lung cancer with chest wall invasion
| WORLD JOURNAL OF SURGICAL ONCOLOGY |
| 2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2021 | The promise of bispecific antibodies: Clinical applications and challenges | CANCER TREATMENT REVIEWS |
| 2019 | The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE |
| 2015 | The regulation of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase by autophagy in low-glycolytic hepatocellular carcinoma cells | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
| 2010 | The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
| YONSEI MEDICAL JOURNAL |
| 2011 | Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. | ANNALS OF THORACIC SURGERY |
| 2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | CLINICAL CANCER RESEARCH |
| 2020 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | LANCET ONCOLOGY |
| 2017 | Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma | ORAL ONCOLOGY |
| 2012 | Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor | DERMATOLOGY |
| 2011 | Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer | JOURNAL OF THORACIC ONCOLOGY |
| 2017 | Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs? | LUNG CANCER |
| 2012 | Treatment outcome of patients with anaplastic thyroid cancer: a single center experience
| YONSEI MEDICAL JOURNAL |
| 2014 | Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors | THORACIC CANCER |
| 2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2012 | Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. | CELLULAR IMMUNOLOGY |
